SM 5887

Known as: SM-5887, SMP-5887 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
SummaryPurpose Amrubicin is a third generation synthetic 9-aminoanthracycline that specifically inhibits topoisomerase II… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
1998
1998
This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
1997
1997
The degree of cardiotoxicity of SM-5887 compared with that of doxorubicin was investigated in rabbits.Two experimental groups… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1992
1992
Pharmacokinetics of SM-5887, a new totally synthetic anthracycline derivative, was studied in a phase I setting by 5-day schedule… (More)
Is this relevant?
1991
1991
A phase II clinical trial of SM-5887, a new totally synthesized anthracycline derivative, was carried out in 13 patients with… (More)
Is this relevant?
1989
1989
The toxicological characteristics of SM-5887 were evaluated in mice after a bolus intravenous injection, and compared with those… (More)
Is this relevant?
1989
1989
The antitumor effects of SM-5887, a totally synthetic 9-aminoanthracycline derivative, were evaluated in six murine experimental… (More)
Is this relevant?
1989
1989
SummarySM-5887, a new totally synthetic anthracycline derivative was studied in a phase I setting. Twenty-nine evaluable courses… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
1988
1988
SM-5887, a new totally synthetic anthracycline derivative, was studied in a phase I setting. Twenty-nine evaluable courses of… (More)
Is this relevant?
1988
1988
SM-5887, a new totally synthetic anthracycline derivative was evaluated the antitumor activity by subrenal capsule assay (SRCA… (More)
Is this relevant?